Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02829034 · ClinicalTrials.gov registry record · Phase 4
Targeting Right Ventricle in Pulmonary Hypertension Gilead
A Phase 4 study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 4
- Development phase
- 22
- Enrollment target
NCT02829034: Completed Phase 4 study, sponsored by University of Pennsylvania.
NCT02829034 is a Phase 4 study that has completed, run by University of Pennsylvania. The registered enrollment target is 22 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02829034, a Phase 4 study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 22 participants
- Enrollment target
Study Summary
This study is looking to see if giving ranolazine to subjects on stable pulmonary hypertension therapies but with right ventricular dysfunction (RVEF \<45%) will improve their health by improving right ventricular (RV) function.
Interventions
- DRUG Placebo
- DRUG Ranolazine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2016-07 |
| Est. Completion | 2018-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02829034
The ClinicalTrials.gov registry entry for NCT02829034 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02829034 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02829034 about?
NCT02829034 is a clinical study titled "Targeting Right Ventricle in Pulmonary Hypertension Gilead". This study is looking to see if giving ranolazine to subjects on stable pulmonary hypertension therapies but with right ventricular dysfunction (RVEF \<45%) will improve their health by improving right ventricular (RV) function.
What is the current status of trial NCT02829034?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 22 participants. The study started on 2016-07. Estimated completion is 2018-01.
What interventions are being tested in trial NCT02829034?
The interventions under investigation include: Placebo (DRUG), Ranolazine (DRUG).
Who is sponsoring clinical trial NCT02829034?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.